Module 3 — Quality (CMC) — GLPI-103
| Field | Value |
|---|---|
| Document ID | M3 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist peptide) |
| Standard | ICH M4Q(R1) (CTD Quality) · Q6B · Q5C · Q3A/B · Q11 |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No CMC wet-lab data are generated by this project. This module presents a scientifically coherent, guideline-structured Quality narrative for a synthetic peptide with two drug products (IV solution, oral tablet). All specifications/values are illustrative.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC / Quality | Initial version (knowledge-based mock) |
3.2.S Drug Substance (GLPI-103)
S.1 General Information
- Nomenclature: GLPI-103 (development code); a synthetic peptide dual agonist of the GLP-1 and Apelin (APJ) receptors.
- Structure: linear/cyclized peptide with sequence and modifications (e.g., fatty-acid acylation for half-life extension, non-natural residues for protease resistance). Defined primary sequence; disulfide/cyclization as applicable.
- Properties: amorphous/lyophilized solid; water-soluble; characteristic isoelectric point; molecular weight in the peptide range.
[MOCK]
S.2 Manufacture
- Manufacturer: named GMP site(s).
- Process (Q11): solid-phase peptide synthesis (SPPS) with fragment coupling, side-chain deprotection, cleavage, and acylation; purification by preparative RP-HPLC; lyophilization. In-process controls at coupling, cleavage, and purification.
- Control of materials & critical steps: defined critical process parameters (coupling efficiency, purification gradient) and acceptance criteria; control strategy per QbD where applicable.
S.3 Characterisation
Primary structure (peptide mapping, MS, amino-acid analysis, sequencing), higher-order structure (CD, NMR as applicable), and impurity characterization (deletion/insertion sequences, oxidation, aggregation/dimers). Biological activity by GLP-1R and APJ potency assays.
S.4 Control of Drug Substance
| Attribute | Method | Acceptance (illustrative) |
|---|---|---|
| Identity | RP-HPLC retention + MS | Conforms |
| Assay (content) | RP-HPLC | 95.0–105.0% |
| Related substances | RP-HPLC | Any single ≤0.5%; total ≤2.0% |
| Aggregates | SEC | ≤1.0% |
| Counterion / water | IC / KF | Within limits |
| Bacterial endotoxin | LAL | ≤ limit (parenteral) |
| Bioburden | Compendial | ≤ limit |
Analytical procedures validated per Q2(R2). Batch analyses and specification justification provided.
S.5 Reference Standards
Qualified primary and working reference standards with characterization and requalification protocol.
S.6 Container Closure
Drug substance stored in qualified containers (e.g., HDPE/foil) protecting from moisture/light.
S.7 Stability (Q5C/Q1A)
Long-term (−20 °C) and accelerated stability support the retest period; stability-indicating methods (RP-HPLC, SEC) demonstrate control of degradation (oxidation, aggregation). [MOCK]
3.2.P Drug Product
Two products are developed: P-IV (solution for IV infusion, once-weekly) and P-Oral (immediate-release tablet with permeation enhancer, once-daily).
P.1 Description & Composition
- P-IV: sterile aqueous solution; buffer, tonicity agent, stabilizer; pH controlled.
- P-Oral: tablet containing GLPI-103, a permeation enhancer (e.g., SNAC-type) to enable oral peptide absorption, plus standard excipients (filler, disintegrant, lubricant).
P.2 Pharmaceutical Development
- Formulation rationale: solubility/stability for IV; enhancer selection and gastro-protection for oral bioavailability (links to biopharmaceutics, M2.7.1).
- Compatibility, robustness, and dissolution development; control of critical quality attributes (assay, impurities, dissolution).
P.3 Manufacture
- P-IV: compounding, sterile filtration, aseptic fill–finish; process validation; sterility assurance.
- P-Oral: blending, compression, (coating), packaging; process validation.
P.4 Control of Excipients
Compendial excipients; the permeation enhancer controlled to its own specification.
P.5 Control of Drug Product
| Attribute | P-IV | P-Oral |
|---|---|---|
| Appearance | Clear solution | Tablet, defined |
| Identity / Assay | RP-HPLC, 95–105% | RP-HPLC, 95–105% |
| Related substances | RP-HPLC | RP-HPLC |
| Dissolution | n/a | Q ≥80% at defined time |
| Uniformity of dosage units | — | Conforms |
| Sterility / Endotoxin | Conforms / ≤ limit | n/a |
| pH / Particulates | Within limits | n/a |
P.6 Reference Standards
As per 3.2.S.5.
P.7 Container Closure
- P-IV: glass vial / stopper, qualified for sterility and compatibility.
- P-Oral: blister/HDPE with desiccant as needed.
P.8 Stability (Q1A/Q5C)
ICH-condition studies (long-term/accelerated) support shelf life and storage statements; stability-indicating methods confirm control of degradation. [MOCK]
3.2.A Appendices
Facilities and equipment; adventitious-agents safety (peptide synthetic origin minimizes viral/TSE risk; any animal-derived raw materials controlled).
3.2.R Regional Information
Region-specific quality information for FDA/EMA/MFDS (e.g., executed batch records, method validation packages, comparability) provided per regional requirements.